CHINA ULCERATIVE COLITIS MARKET ANALYSIS

China Ulcerative Colitis Market, by Drug Therapy (5-Aminosalicylates {Mesalazine, Balsalazide, Olsalazine, and Others}, Monoclonal Antibodies {Vedolizumab, Adalimumab, Infliximab, Golimumab, and Ustekinumab}, Steroids {Budesonide, Prednisone, Beclomethasone, Deflazacort, and Others}, Antibiotics, Late Stage Pipeline Molecules {Zeposia, Etrasimod and Others}, and Other Drugs), by Dosage Form (Oral and Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : May 2022
Code : CMI4862
Pages :408
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

China Ulcerative Colitis Market – Competitive Landscape

Major players operating in the China ulcerative colitis market include AbbVie Inc, Celltrion Healthcare, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche AG, Arena Pharmaceuticals, Takeda Pharmaceuticals Company Ltd., GlaxoSmithKline Plc., Eli Lilly and Company, AstraZeneca, Pfizer Inc., Amgen Inc., BRISTOL-MYERS SQUIBB, ZERIA Pharmaceutical Co., Ltd., InDex Pharmaceuticals Holding AB, Mitsubishi Tanabe Pharma Corporation, Salix Pharmaceuticals, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., EA Pharma Co., Ltd., Theravance Biopharma, and HUTCHMED

China Ulcerative Colitis Market – Competitive Landscape